Dr. Kanaa's research primarily revolves around understanding and mitigating complications that can arise from critical medical treatments. He studies conditions such as angioedema, a potentially life-threatening swelling that can occur after receiving a medication for strokes, and deep vein thrombosis, a serious condition affecting blood circulation that can result from heart procedures. Moreover, Dr. Kanaa investigates the effectiveness of new solutions like Cathasept to reduce infections in hemodialysis catheters, as well as the side effects linked to treatments for acute promyelocytic leukemia, such as painful skin ulcers. His findings help improve patient care and guide healthcare providers in managing risks associated with these treatments.
Key findings
In his study on angioedema, Dr. Kanaa highlighted that while swelling from tissue plasminogen activator usually resolves on its own, it can block airways and become life-threatening if not treated promptly.
Dr. Kanaa identified a link between femoral artery pseudoaneurysm and deep vein thrombosis, showing successful non-surgical treatment in a unique case.
Using Cathasept for tunneled hemodialysis catheters, his research found a significant reduction in catheter colonization rates to 0.14 cases per 1,000 catheter-days, compared to 1.08 with traditional heparin.
In a study involving 44 tunneled hemodialysis catheters, 36% showed signs of microbial colonization, indicating a significant infection risk.
Among patients treated with all-trans retinoic acid for acute promyelocytic leukemia, Dr. Kanaa reported that about 12% developed painful scrotal ulcers within 9 to 13 days of starting treatment.
Frequently asked questions
Does Dr. Kanaa study complications related to stroke treatments?
Yes, Dr. Kanaa's research includes angioedema, a serious swelling that can occur after receiving tissue plasminogen activator for strokes.
What infections does Dr. Kanaa focus on in his research?
He studies infections associated with tunneled hemodialysis catheters and compares new solutions to reduce these risks.
Is Dr. Kanaa’s work relevant for patients undergoing cancer treatment?
Yes, he has researched side effects related to treatments for acute promyelocytic leukemia, including painful skin ulcers.
What conditions does Dr. Kanaa help inform treatment for?
His work informs treatment for conditions like deep vein thrombosis related to heart procedures and complications from stroke treatments.
How does Dr. Kanaa's research help healthcare providers?
His findings guide healthcare providers in understanding and managing risks associated with various treatments, enhancing patient safety.
Publications in plain English
Iatrogenic Pseudoaneurysm: An Uncommon Cause of Deep Vein Thrombosis.
2018
Cureus
Khalid M, Murtaza G, Kanaa M, Ramu V
Plain English This study looked at a specific problem called femoral artery pseudoaneurysm (FAP) that can happen after a heart procedure. Researchers described a case where FAP caused a rare issue called deep vein thrombosis (DVT) in the leg, which was successfully treated without surgery. Understanding this link is important because it highlights a potential complication that doctors need to be aware of after certain heart procedures.
Who this helps: This helps doctors and patients undergoing cardiac catheterization.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
2018
Cureus
Khalid M, Kanaa M, Alkawaleet Y, Ayub MT
Plain English This study looked at angioedema, a swelling that can happen after a treatment called tissue plasminogen activator (tPA) used for strokes. It found that this type of swelling can affect the face and throat, and while it often resolves on its own, it can sometimes block airways and become life-threatening if not treated quickly. Understanding this risk is important for ensuring that healthcare providers can respond effectively to keep patients safe.
Who this helps: This helps patients receiving tPA after a stroke and the doctors treating them.
Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial.
2015
American journal of kidney diseases : the official journal of the National Kidney Foundation
Kanaa M, Wright MJ, Akbani H, Laboi P, Bhandari S +1 more
Plain English This study looked at a new solution called Cathasept to see if it could reduce infections in patients with tunneled hemodialysis catheters compared to the traditional heparin solution. The results showed that catheter colonization rates were much lower with Cathasept — 0.14 cases per 1,000 catheter-days compared to 1.08 for heparin. However, patients using Cathasept faced more complications related to catheter blockage.
Who this helps: This helps patients undergoing hemodialysis by potentially lowering the risk of catheter colonization.
Examination of tunnelled haemodialysis catheters using scanning electron microscopy.
2010
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Kanaa M, Wright MJ, Sandoe JA
Plain English This study looked at tunnelled haemodialysis catheters to see how often they are colonized by germs. Researchers examined 44 segments from these catheters using a special tool and found that 36% showed signs of microbial colonization, while only 18% tested positive when using a different method. This matters because infections related to these catheters can lead to serious health issues for patients.
Who this helps: Patients needing haemodialysis.
Scrotal ulceration during all-trans retinoic (ATRA) therapy for acute promyelocytic leukaemia.
2000
Clinical and laboratory haematology
Charles KS, Kanaa M, Winfield DA, Reilly JT
Plain English This study looked at the painful skin ulcers that appeared on the scrotum of two patients receiving all-trans retinoic acid (ATRA) for acute promyelocytic leukaemia (APL). Both patients developed these ulcers within 9 to 13 days of starting treatment, and about 12% of the 17 APL patients treated at the authors' institution over ten years experienced similar issues. Recognizing this side effect is important because it helps to better manage the treatment and care of patients undergoing ATRA therapy.
Who this helps: This information benefits patients being treated with ATRA and their doctors.
Muhammad Khalid Yazan Alkawaleet Muhammad Talha Ayub Ghulam Murtaza Vijay Ramu Mark J Wright Habib Akbani Paul Laboi Sunil Bhandari Jonathan A T Sandoe
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.